Mersana Therapeutics, Inc. (MRSN)
Market Cap | 598.02M |
Revenue (ttm) | 36.86M |
Net Income (ttm) | -171.67M |
Shares Out | 120.58M |
EPS (ttm) | -1.48 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 3,198,952 |
Open | 5.020 |
Previous Close | 5.040 |
Day's Range | 4.550 - 5.040 |
52-Week Range | 0.801 - 9.620 |
Beta | 1.51 |
Analysts | Buy |
Price Target | 5.57 (+14.61%) |
Earnings Date | May 7, 2024 |
About MRSN
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in Nove... [Read more]
Financial Performance
In 2023, MRSN's revenue was $36.86 million, an increase of 38.65% compared to the previous year's $26.58 million. Losses were -$171.67 million, -15.94% less than in 2022.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for MRSN stock is "Buy." The 12-month stock price forecast is $5.57, which is an increase of 14.61% from the latest price.
News
Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-d...
Mersana Therapeutics to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-d...
Mersana Therapeutics to Host Fourth Quarter and Year End 2023 Conference Call on February 28, 2024
CAMBRIDGE, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-d...
Mersana Therapeutics to Participate in Guggenheim's 6th Annual Biotechnology Conference
CAMBRIDGE, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-d...
Mersana Therapeutics Announces Business Updates, Expected 2024 Milestones and Upcoming Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-d...
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-dr...
Mersana Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results
CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-d...
Mersana Therapeutics to Host Third Quarter 2023 Conference Call on November 7, 2023
CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-d...
Mersana Therapeutics Announces FDA has Lifted Clinical Hold on Phase 1 Clinical Trial of XMT-2056
CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-d...
Mersana Therapeutics Announces Changes in Leadership
CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mersana Therapeutics, Inc. - MRSN
NEW YORK , Aug. 18, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Mersana Therapeutics, Inc. ("Mersana" or the "Company") (NASDAQ: MRSN). Such investors are advi...
Mersana Therapeutics Announces Second Quarter 2023 Financial Results
CAMBRIDGE, Mass., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-d...
Mersana Therapeutics Announces Topline Data from UPLIFT Clinical Trial in Patients with Platinum-Resistant Ovarian Cancer and Strategic Reprioritization
CAMBRIDGE, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-d...
MRSN FRAUD ALERT: Jakubowitz Law is Investigating Mersana Therapeutics, Inc. in Connection with Potential Violations of Federal Securities Laws
NEW YORK , June 27, 2023 /PRNewswire/ -- Jakubowitz Law announces that an investigation into potential securities fraud allegations has commenced on behalf of shareholders of Mersana Therapeutics, Inc...
MRSN NEWS: The Klein Law Firm Initiates an Investigation Involving Possible Securities Fraud Violations by Officers of Mersana Therapeutics, Inc.
NEW YORK , June 27, 2023 /PRNewswire/ -- The Klein Law Firm announces that it is investigating allegations that Mersana Therapeutics, Inc. ("Mersana") (NASDAQ: MRSN) violated federal securities laws. ...
MRSN ALERT: The Law Offices of Vincent Wong Investigate Mersana Therapeutics, Inc. for Potential Violations of Securities Laws
NEW YORK , June 26, 2023 /PRNewswire/ -- Attention Mersana Therapeutics, Inc. ("Mersana") (NASDAQ: MRSN) shareholders: The Law Offices of Vincent Wong announce that an investigation has commenced into...
MSN ALERT: The Law Offices of Vincent Wong Investigate Mersana Therapeutics, Inc. for Potential Violations of Securities Laws
NEW YORK , June 22, 2023 /PRNewswire/ -- Attention Mersana Therapeutics, Inc. ("Mersana") (NASDAQ: MRSN) shareholders: The Law Offices of Vincent Wong announce that an investigation has commenced into...
MRSN INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Mersana Therapeutics, Inc.
NEW YORK , June 21, 2023 /PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced an investigation of Mersana Therapeutics, Inc. ("Mersana") (NASDAQ: MRSN) concerning possible violati...
US FDA puts Mersana Therapeutics' ovarian cancer drug studies on partial hold
Mersana Therapeutics Inc said on Thursday the U.S. Food and Drug Administration (FDA) had put a partial clinical hold on its ovarian cancer drug studies and paused patient enrollment, citing safety co...
Mersana Therapeutics stock craters after FDA halts trials of ovarian cancer treatment after bleeding events
Mersana Therapeutics Inc.'s stock MRSN cratered 73% premarket Thursday, after the company announced that the U.S. Food and Drug Administration had placed a partial clinical hold on two trials of a tre...
Mersana Therapeutics Announces Partial Clinical Hold on UP-NEXT and UPGRADE-A Clinical Trials
CAMBRIDGE, Mass., June 15, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-d...
Mersana Therapeutics Provides Business Update and Announces First Quarter 2023 Financial Results
CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-dr...
Mersana Therapeutics to Present at Bank of America Securities 2023 Healthcare Conference
CAMBRIDGE, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-dr...
Mersana Therapeutics to Host First Quarter 2023 Conference Call on May 9, 2023
CAMBRIDGE, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-dr...
Mersana Therapeutics Announces Upcoming Presentations at 2023 ASCO Annual Meeting
CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-...